The PharmAla
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Adelaide St E Ste 801, Toronto, Ontari...Phone Number
(855) 444-6362Website
www.pharmala.caRevenue
<$5 MillionStock Symbol
MDMAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About The PharmAla
PharmAla Biotech Holdings Inc. is a Canadian biotechnology company focused on the research, development, manufacturing, and supply of clinical-grade MDMA and related MDXX class molecules for use in regulated research and therapeutic settings. The company was founded with the goal of alleviating the global shortage of generic, clinical-grade MDMA to support clinical trials and develop novel compounds with improved safety profiles, using a regulatory-first approach that emphasizes compliance with health authorities. PharmAla works with established laboratories across Canada to produce its products under Good Manufacturing Practice (GMP) standards and is involved in preclinical research and partnerships aimed at expanding access to its therapies in select jurisdictions.Explore more
The PharmAla Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is The PharmAla your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on The PharmAla recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at The PharmAla
Click to see if The PharmAla had a recent Job posting/layoffs
Check if The PharmAla has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
The PharmAla, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when The PharmAla launches new products
Check out if The PharmAla is spiking on competitors!
Funding: Get notified immidiatlly once The PharmAla has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to The PharmAla
Compare insights from companies similar to The PharmAla, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
The PharmAla is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
The PharmAla is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about The PharmAla.
The PharmAla Tech Stack
A closer look at the technologies used by The PharmAla
Most Recent Scoops
Partnership
Project
Partnership, Product Management, Business Development, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals, Manufacturing Operations
Partnership
The PharmAla has established partnerships to supply its MDMA products to patients, doctors, and institutions in multiple countries. The company is supplying to the U.S. Veterans Affairs Administration, U.S. military, major universities, and has signed distributors in New Zealand, the Netherlands, Switzerland, and the Czech Republic.
Healthcare Technology
Project
The PharmAla has developed multiple MDMA-based products: Linneo (generic MDMA), ALA-02 (a safer MDMA variant for social anxiety), and APA-01 (for neurological disorders). APA-01 is designed to regrow neuronal connections in damaged parts of the brain.
Product Development, Medical Research, Pharmaceuticals
Project
The PharmAla is the world's leading manufacturer and supplier of MDMA for clinical use, with a first-mover advantage in every market where it sells. The company is also developing patented novel chemical entities based on MDMA for various indications.
Product Development, Pharmaceuticals, Manufacturing Operations
Project
Product Development, Healthcare Technology
The PharmAla News & Media
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease programPharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
PharmAla signs definitive agreement with Jupiter Neurosciences to out-license their patented ALA-002 molecule, securing up-front and development payments.PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset
PharmAla announces the completion of manufacture of ALA-002 drug substance, as well as a full operational update on the LaNeo Gen 2 patented drug family.PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002 to Jupiter Neurosciences in a Transaction Valued at Over $100 Million USD
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding The PharmAla
Sign Up For FreeTo access detailed company insights
PharmAla Biotech Holdings Inc. is a Canadian biotechnology company focused on the research, development, manufacturing, and supply of clinical-grade MDMA and related MDXX class molecules for use in regulated research and therapeutic settings. The company was founded with the goal of alleviating the global shortage of generic, clinical-grade MDMA to... Read More
